AegisCN LLC: Clinical Trials

3 trials sponsored by AegisCN LLC, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2
Phase 11Completed 1

Follow AegisCN LLC: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of CN-105 in Subject With Acute Supratentorial Intracerebral Hemorrhage
Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2)., 0.9% Sodium-chloride - Intracerebral Hemorrhage
Phase 2CompletedNational Neuroscience Institute602019-03-242022-12-01
A Proof of Concept Study to Evaluate CN-105 in ICH Patients
CN-105 - Intracerebral Hemorrhage
Phase 2CompletedAegisCN LLC382017-08-282020-03-11
Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage
CN-105, Placebo - Intracerebral Hemorrhage (ICH)
Phase 1CompletedAegisCN LLC482015-12-012016-08-18

Conditions studied

Cerebral Hemorrhage (3)

Interventions

apolipoprotein E mimetic peptide CN-105 (2)  ·  Sodium Chloride (1)

Countries

United States (2)  ·  Singapore (1)

Top investigators

Michael L James, MD (1)

Results publications

PMID 35562205, PMID 11161595, PMID 11590206, PMID 14671250, PMID 16179504, PMID 27713572, PMID 27990643, PMID 28429734, PMID 42332280, PMID 9184634